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Abstract
Long-chain 3-Hydroxyacyl CoA Dehydrogenase Deficiency (LCHADD) is an autosomal
recessive defect in fatty acid oxidation that presents with hypoketotic hypoglycemia and/or
hypertrophic cardiomyopathy in infancy, and recurrent rhabdomyolysis in adolescence, however,
sudden cardiac death has not been a previously reported complication of LCHADD. We have
conducted a case review study comparing young adult LCHADD patients who have experienced
sudden cardiac arrest events (n=5) to similar patients who have not (n=5) for the purpose of
evaluating associated cardiac risk factors. We reviewed medical records from ECG tests,
hospitalization reports, acylcarnitine, and complete metabolic panels, clinic notes, and autopsy
reports. Retrospective chart review has led to no certain etiology however, electrolyte
derangements, low free carnitine and elevated total to free carnitine ratio have been noted upon
hospitalization in sudden cardiac arrest cases. At the time of the sudden cardiac death event, only
one subject was in a metabolic crisis with elevated creatine phosphokinase levels. Lifethreatening ventricular arrhythmias appear to be a newly recognized life-threatening
complication in the adolescent and young adult age groups of LCHADD patients. The exact
mechanism underlying the sudden death events is not understood and there are no current
therapies. Understanding the pathophysiology of inherited arrhythmias can be challenging due to
the complexity of both the heart and LCHAD deficiency along with the lack of appropriate
cellular and in vivo models. Recent advances in human-induced pluripotent stem cell (hiPSC)
technology have provided extraordinary progress in understanding the mechanisms in generating
human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Future directions of
this study seek to generate LCHAD deficient patient-derived iPSC-CMs in order to assess
mitochondrial function, force of contraction, oxygen consumption rates, impacts of analytes, and
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calcium regulation. In a paper published in the Nature Methods Journal, Burridge and colleagues
establish an easily reproducible protocol for the chemically defined generation of human
cardiomyocytes (Burridge, Matsa, & Shukla, 2014) from skin fibroblast-derived induced
pluripotent stem cells. Our research lab will establish this method which utilizes three crucial
components of a chemically defined medium consisting of the basal medium RPMI 1640, Lascorbic acid 2-phosphate along with recombinant human albumin to generate cardiomyocytes
with an immature phenotype. This chemically defined medium will provide reproducible,
scalable methods for deriving cardiomyocytes from iPSCs however, they do remain immature in
nature and future directions of the study seek to adapt newly engineered maturation protocols.
Assessing the disruption of bioenergetics and mitochondrial function in hiPSC-CMs will provide
a meaningful in vitro model to examine the potential pathways and biochemical mechanisms that
contribute to cardiac arrhythmias observed in affected LCHADD patients who have experienced
sudden cardiac death events. Ultimately, clinical trials will be needed to further characterize the
pathophysiology of these severe cardiac manifestations in young adult LHCADD populations.
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Introduction
Fatty Acid (FA) Metabolism
Metabolism is an essential process that occurs in every living organism. It’s a term that
describes all the chemical reactions that occur within living cells that function to either convert
food into energy through a process of catabolism or to convert small nutrients into large
molecules through anabolism. In living organisms, fatty acids (FAs) are critical and essential fuel
sources in the body that consist of certain fats we obtain through the food we consume. When
digestion occurs, the body breaks down fats into fatty acids which can then be absorbed into the
blood and transported throughout the body. Fatty acids have many important functions in the
body including energy storage, maintenance of cellular membranes, and as a major source of
fuel. Lipolysis of fats in the body is a biochemical process that occurs in the cytoplasm of a cell
where large FAs such as triglycerides can be broken down into smaller substituents of glycerol
and three molecules of FAs which enter the mitochondria to further metabolism. Three types of
fatty acid oxidation processes that occur in the body include mitochondrial-β oxidation,
microsomal ω-oxidation, and peroxisomal β-oxidation which all differ vastly from each other.
Mitochondrial beta-oxidation is one of the most crucial pathways in living organisms that
oxidize the released FAs from triglycerides into two carbon units of acetyl CoA. Fatty acid
oxidation (FAO) occurs through an orchestration of over 20 different enzymes that form the
pathway and allow oxidation to occur. The movement and shuttling of FAs from the cytosol into
the mitochondria for oxidation are credited to a set of enzymes known as carnitine palmitoyltransferase shuttles. Long-chain fatty acyl-CoA enters the outer membrane of the mitochondria
and is converted to a long-chain fatty acyl-carnitine by carnitine palmitoyl-transferase 1. The
fatty acylcarnitine is transported into the mitochondria by carnitine palmitoyl-transferase and the
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fatty acyl-CoA is reformed by carnitine palmitoyl-transferase II allowing for further oxidation
and the crucial steps of beta-oxidation occur.

Mitochondrial β-Fatty Acid Oxidation
Beta oxidation produces a lot of ATP allowing living cells to meet high energy demands
and, maintain internal homeostasis, especially during variations in internal or external
environmental conditions. Conditions that increase cellular energy needs include disease,
exercise and durations of fasting. Oxidation of fatty acids is necessary to meet these energy
demands and requires a series of complex enzymes one of which is, the mitochondrial
trifunctional protein (MTP). MTP is a multienzyme complex situated in the inner mitochondrial
membrane that is constituted of four alpha subunits, and four beta subunits. The HADHA gene
encodes the alpha subunit of the MTP complex and the HADHB gene encodes the beta subunit
of the MTP complex which are responsible for catalyzing the last three steps of mitochondrial
beta-oxidation of long-chain fatty acids (LCFAs). The HADHA gene is responsible for
catalyzing the 3-hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities whereas
the HADHB gene is responsible for catalyzing the 3-ketoacyl-CoA thiolase activity. A number
of fatty acid oxidation disorders (FAODS) are caused by genetic defects in the enzymes
responsible for the transport of fatty acids in the mitochondria and for the oxidation of fatty acids
in the mitochondria (Wilcken, 2010). A deficiency of any one of the enzymes listed above, could
cause direct blocks in crucial pathways of fatty acid oxidation resulting in FAODs. Organs that
particularly rely on FAO include the liver, eyes, muscle, and the heart which can become
severely adversely affected by FAODs that block these processes from properly occurring
(Wajner, 2016).
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Fatty Acid Oxidation Disorders (FAODs)
FAODs are autosomal recessively inherited disorders which is one of several ways that a
disease can be passed through families throughout generations. For autosomal recessive
inheritance to occur, two copies of a gene in a cell are mutated and each parent will carry one
copy of the mutated gene however, they typically do not present with any symptoms of the
condition which implies that we can see the disease skip through generations in a family. Some
of the common FAODs include short-chain acyl-CoA dehydrogenase (SCAD), medium-chain
acyl-CoA dehydrogenase (MCAD), long-chain 3-hydroxyacyl CoA dehydrogenase (LCHAD),
and very long-chain acyl-CoA dehydrogenase (VLACD) deficiencies. Of these enzyme
deficiencies, the four most prevalent deficiencies in the long-chain fatty acid oxidation pathway
are CPT-II, VLCAD, LCHAD, and MTP deficiencies. Figure 1 below includes the details of
presentation and diagnostic criteria of the long-chain fatty acid deficiencies.

Figure 1. A table indicating the various long-chain fatty acid oxidation disorders and their typical
presentations and diagnosis (Merritt, 2018)
7

Initial presentations of several FAODs are seen in the neonatal period with severe
symptoms including hypoketotic hypoglycemia, cardiomyopathy, liver dysfunction, and
retinopathy which are common and sometimes, also continue to present into infancy and early
childhood. Episodic rhabdomyolysis is the breakdown of damaged skeletal muscle which causes
the release of myoglobin. This release results in extreme pain in patients and is a frequent
presentation during or after adolescence in those with long-chain FAODs (Merritt, 2018).
Research suggests that individuals with FAODs accumulate toxic byproducts in the blood stream
such as long-chain fatty and hydroxy acids, and fatty acyl-carnitines. Newborns with FAOD tend
to experience multi-organ failure of varying severities which can become worse under stressed
conditions that exacerbate energy use especially during times of fasting, illness or with
prolonged exercise.

Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency
Long-chain 3-Hydroxyacyl-Coenzyme A Dehydrogenase deficiency (LCHADD) is part
of the fatty acid oxidation disorders (FAOD) family of disorders. LCHADD is the result of a
mutation in the alpha subunit of the MTP, HADHA. Mutation in the active site residue of the
HADHA gene (1528G>C) is responsible for the loss of LCHAD enzyme activity. Classic
symptoms of infants with LCHADD include recurrent hypoglycemia induced by fasting or
physiologic stress, and recurrent rhabdomyolysis or exercise intolerance which can also induce
overwhelming neonatal cardiomyopathy in young children and infants (Vockley, 2017).
Newborn screening (NBS) for fatty acid oxidation disorders, including LCHADD, was started in
Oregon in 2004. Today, most infants have the opportunity to become diagnosed at an early age
allowing for prompt medical care before a catastrophic metabolic decompensation occurs
(Frazier, 2006).
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Prior to the advent of NBS, hypertrophic and dilated cardiomyopathy in infants was a
frequently documented complication of LCHADD. Upon diagnosis and treatment, the
cardiomyopathy typically resolves and patients have reported normal cardiac function in
childhood. However, recently, there have been 7 known cases of sudden ventricular tachycardia
(VT) in adolescent and young adults with LCHADD between 16 and 23 years of age. Acute VT
in the absence of hypertrophic cardiomyopathy appears to be a late complication observed in
some adolescent and young adults with LCHADD that is not currently described in the literature.
At a scientific meeting in 2013, our research group reported a short case series (3
subjects) of patients with LCHADD who had experienced sudden cardiac arrest events. Since
then, 4 other cases have appeared. Medical records of 5 patients with LCHADD and sudden
cardiac arrest have been reviewed. Of these patients, 4 were resuscitated and 1 was deceased.
Three patients received an implantable cardioverter. Medical records of 5 patients with
LCHADD of similar age who have not had a cardiac arrest were also reviewed and utilized for
comparison. While electrolyte derangements are reported in the record, we hypothesize that
unidentified underlying cardiac risk factors that increase the risk for sudden cardiac arrest may
exist. To date, there are 7 known or suspected cases of sudden VT in adolescent and young
adults with LCHADD in an estimated population of 60 patients >16 years of age in the U.S., thus
becoming a significant medical problem for this specific patient population. Sudden cardiac
arrest episodes have also become of concern to other patients with LCHADD and their families,
who are now enquiring whether prophylactic implantable cardioverters should be considered for
primary prevention of a sudden VT event in young adult LCHADD patients. A thorough cardiac
evaluation has not been performed among these patients and specific risk factors have not yet
been identified. A recent grant and IRB study submission to conduct more thorough cardiac
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evaluation for patients described here was submitted and approved. Recruitment was about to
start but due to the impacts of COVID-19, the study enrollment was postponed an indefinite
amount of time. The lack of thorough cardiac data from this extremely rare and limited study
population and the lack of an appropriate cellular model are two of the essential motivations
behind the current line of research into sudden cardiac death in LCHADD patients.

Central Hypothesis, Purpose, and Specific Aims
Establishing a cellular model to further research sudden cardiac death in LCHADD
patients is a major goal of this study which will also entail additional protocols and materials to
generate cardiomyocytes with a mature phenotype that are capable of oxidizing fatty acids. In a
paper published in the Nature Methods Journal, Burridge and colleagues establish a reproducible
protocol for the chemically defined generation of human cardiomyocytes from skin fibroblast
derived, induced pluripotent stem cells. This protocol was adapted by our lab to generate
cardiomyocytes with an immature phenotype which was successful prior to the institution of
modified research due to the COVID-19 pandemic.
The initial stage of cardiomyocyte generation involves three crucial components of a
chemically defined medium consisting of the basal medium RPMI 1640, L-ascorbic acid 2phosphate along with recombinant human albumin, and small-molecules responsible for cellular
signaling. This chemically defined medium will provide a reproducible, scalable method for
deriving cardiomyocytes from human induced pluripotent stem cells that begin immature and
fetal like in nature. In another study, a research group from the University of Washington School
of Medicine generated matured human induced pluripotent stem cell cardiomyocytes (hiPSCCMs) by engineering a microRNA maturation cocktail known as MiMaC consisting of Let7i OE,
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miR-452 OE, miR-122 KO, and miR-200a KO which greatly reduced the complete time of the
protocol. One of the key differences during maturation is the switch from glycolysis to oxidative
phosphorylation for energy production, including fatty acid oxidation. Once mature hiPSC-CMs
have been generated, our study will aim to assess the functionality of hiPSC-CMs by measuring
and comparing force of contraction, oxygen consumption rates, beat rates, and calcium
regulation in LCHADD patient derived iPSC-CMs compared to normal healthy iPSC-CMs.
Other studies have also suggested that accumulation of long-chain hydroxyl acyl-CoA
esters and/or the long chain 3-hydroxylated fatty acids (LCHFA) and particularly, 3hydroxypalmitic acid (3HPA) in patients can have an effect on mitochondrial respiratory
parameters measured by oxygen consumption in intact cell system consisting of heart fibers,
cardiomyocytes, hepatocytes, and brain slices (Cecatto, Wajner, Vargas, 2018). This research has
explored the potential effects of pathological concentrations of toxic byproducts (LCHFAs and
3HPAs) formed by LCHADD patients postulating toxicity as one particular mechanism of
sudden ventricular death in this population. When the LCHAD enzyme is missing, accumulated
levels of long-chain 3-hydroxylated fatty acids (LCHFA), particularly 3-hydroxypalmitic acid
(3HPA) and their carnitine conjugates can be seen in patients’ bloodstream. Diagnoses of
mitochondrial fatty acid oxidation disorders like LCHADD are typically based on increased
concentrations of long-chain 3-hydroxyacylcarnitines in plasma and excessive urinary excretion
of 3-hydroxy-carboxlyic acids, especially during or after a metabolic decompensation (den Boer,
2002). Symptoms often develop in the presence of episodes of illness or fasting which affect
organs that predominantly use long-chain fatty acids for means of energy such as the heart, liver,
retinal, and skeletal muscle.
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An additional avenue to the current study is to investigate the effects of LCHAD
deficiency and the presence of long-chain 3-hydroxylated fatty acids, (which accumulates the
most in LCHAD deficiency), on mitochondrial respiratory parameters measured by oxygen
consumption, and cardiac electrophysiology in intact cell systems of human induced pluripotent
derived stem cells that have been differentiated into cardiomyocytes. Measurement of other
crucial mitochondrial functions including membrane potential, Ca2+ retention capacity, beat force
and contraction rate, in cardiomyocytes derived from LCHAD patients who have and have not
experienced severe cardiac death events will be useful in our exploration.
The answers to the following research questions is what the study seeks to explore:
-

How are mitochondrial parameters such as oxygen consumption and various cardiac
electrophysiological functions affected in LCHAD deficient patient derived, induced
pluripotent stem cells differentiated into cardiomyocytes?

-

How may the pathological concentrations of long chain 3-hydroxylated acids such as
3HPA affect bioenergetics and overall function of LCHAD deficient, mature
cardiomyocytes?

Patients
Adolescent and young adult patients with confirmed LCHAD deficiency having
consented, in compliance with the Helsinki Declaration, to the collection and use of their medical
records for future research through our “Fatty Acid Oxidation Disorders Tissue Repository”
(IRB #8561) were enrolled in this retrospective case study (IRB #18446). Medical records
including results assessed from electrocardiogram (ECG) tests, hospitalization reports,
acylcarnitine and complete metabolic panels, clinic and laboratory notes, and autopsy reports
12

were obtained for review. Medical records of 10 patients were reviewed and patients split into
two groups according to whether they had a history of sudden cardiac arrest (SCA) (N=5) or had
no history of SCA (‘controls’, N=5). In patients with a history of SCA, 4 were resuscitated and 1
is deceased following SCA. Age range at 1st cardiac event was 15-21 years, with current age at
time of review of 19-27 years. In ‘controls’ without history of SCA, 2 died of cardiac
abnormalities not related to SCA. Current age ranges of ‘controls’ at time of review was 19-25
years.

Methodology
Skin fibroblasts obtained from LCHADD patients in a separate IRB protocol (IRB#8561)
can be used to generate induced pluripotent stem cells. Fibroblasts are reprogrammed in our lab
by integration-free Sendai virus vectors which can then induce the formation of stem cells.
hiPSCs can then be differentiated and used for further experiments. Our research lab has
experience differentiating iPSCs to human retinal pigmented epithelial cells however, generation
of hiPSC derived cardiomyocytes has not yet been attempted. It is our hope to establish a reliable
protocol to differentiate hiPSCs to mature cardiomyocytes in order to carry out experiments that
concern the electrophysiology and overall function of LCHAD deficient cardiomyocytes. This
will provide an in vitro model to investigate potential mechanisms associated with arrythmias in
human patients. Through the establishment of a cellular model, we hope this will provide a
critical research tool that has the potential to further understand the mechanisms of arrythmias in
patients.
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Cell Cultures
Skin fibroblasts derived from patients and other similar somatic cell types lack high
expression of the transcription Oct4, Sox2, Klf4, and c-Myc under normal condition. Once high
levels of expression for these four genes are achieved, a fibroblast can become reprogrammed to
pluripotent cell types. Induced pluripotent stem cells (iPSC) are genetically reprogrammed adult
cells which exhibit a pluripotent stem cell-like state similar to embryonic stem cells (Takahashi
et al., 2007). There are multiple ways of generating iPSCs which include retrovirus-mediated
gene transduction and chemical induction. DNA-based vectors that include adenovirus, or
plasmid vectors do not require integration into the hosts chromosomes and therefore allow the
cells to reprogram with non-integrating episomal DNA vectors. Sendai virus is a single stranded
negative-sense RNA virus that replicates in the cytoplasm and produces very high copy numbers
of the target gene. The Sendai viral vector can be used to efficiently express all four factors
stably without chromosomal integration and can be eliminated completely from reprogrammed
skin fibroblast cells. Once iPSCs have been generated, cells can be inducted into three different
potential layers that include the ectodermal (neuron, astrocytes, Retinal Epithelial cells (RPE)),
endodermal (lung, thyroid, pancreatic cells), or into the mesoderm layer (cardiac and skeletal
muscle cells, tubule cells of the kidney, or red blood cells) (Millipore Sigma, 2016).

Cardiomyocyte Differentiation
To further reveal the disease etiology of the sudden cardiac death events we will
differentiate induced pluripotent stem cells (iPSCs) into cardiomyocytes which will inherit the
genetics found in skin fibroblasts from LCHAD deficient patients that were enrolled into the
study rendering these CMs as LCHAD deficient. In the past decade, many methods have been
14

developed that successfully differentiate iPSCs into cardiomyocytes. While this study seeks to
establish an in vitro model to study potential mechanisms of SCD, this model is anticipated to
still be largely limited in its implications to be made in relation to LCHADD patients who
experience differences in physiology, course of medical history, and compliance to diet.
Advantages of using hiPSC-CMs include their ability to replicate the genome of the patient
donor to allow for characterization of numerous disease states and drugs, as well as their ability
to contract which allows for a model of cardiac contractility and electrophysiology. Despite the
ability to model biochemical mechanisms in one’s body, this approach is still highly limited in
being able to translate the results in human subjects.
hiPSC-CMs also have limitations due to their immaturity as they represent fetal
cardiomyocytes instead of full-functioning, adult cardiomyocytes. A protocol adapted from
Burridge and colleagues will be utilized in this experiment to generate an initial and immature
cardiomyocyte model. Though this model has been adequately optimized to generate beating
iPSC-CMs, the resulting cells remain highly immature in their nature in regards to their structure
and function. These immature cardiomyocytes which rely on glycolysis to produce energy
(instead of fatty acid utilization), experience reduced contractile and electrophysiological
function and structure, and exhibit disorganized morphologies. Recent research has established
that disease modelling using immature iPSC-CMs may be inaccurate and limited in their utility,
particularly for investigating the impacts of a defect in fat oxidation. This weakness in the
literature has been widely addressed and numerous groups have made efforts to establish
methods of maturing cardiomyocytes. We will aim to review and replicate successful methods
that have been developed for the maturation of human iPSC-CMs using small molecules,
environmental manipulation, prolonged cell-culturing, or 3-dimensional growth approaches.
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The same research group at the University of Washington recently published a paper
addressing a successful method of maturing iPSC-CMs through addition of small molecules and
environmental manipulation approaches of matured iPSC-CMs (Miklas, Clark, Levy, & Detraux,
2019). The research group engineered a microRNA maturation cocktail known as MiMaC
consisting of mix of specific micro-RNAs that alter gene expression: Let7i OE, miR-452 OE,
miR-122 KO, and miR-200a KO. Upon functional assessment of cardiomyocytes treated with
MiMaC, an increase in parameters such as twitch force, power, cell area, and the ability to utilize
palmitate more efficiently than control CMs was reported. Once mature phenotype exhibiting
hiPSC-CMs have been generated that exhibit optimal mechanical and electrical stimulation,
further studies of cell bioenergetics and mitochondrial function can be properly assessed.

Platforms for Functional Analysis of hiPSC-CMs
Using iPSC technology, we will produce a model of LCHADD patient specific
cardiomyocytes to investigate potential mechanisms for sudden conduction arrhythmias. A
crucial step for this procedure will be to characterize and confirm gene expression patterns and
comparing mRNA levels in samples of cardiomyocytes that are produced. Measuring and
characterizing the mRNA expression in cardiomyocytes will entail the use of quantitative
polymerase chain reaction (qPCR). By using qPCR, protein expression analyses can be done to
explore the physiological role of various channels in cardiomyocytes – in this case expression of
calcium channels in LCHADD CMs will be assessed against normal, wildtype (WT) cells under
normal or high fat media concentrations. In addition to this measure, the following list provides
an overview of methodology that will be used to assess various patient specific iPSC-CM
functionalities.
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Patch Clamp: Patch clamps include high conformity intracellular electrical recordings from
cardiomyocytes that can provide detailed and precise assessments of the electrophysiological
properties of CMs. Sharp electrodes that can penetrate the membrane of CMs can measure
membrane potential and thus, characterize action potentials.
Multielectrode Array: This method includes a noninvasive and nonterminal method that will
allow for long-term measurements of extracellular field potential signals from monolayers of
hiPSC-CMs. CMs can be plated on the walls of the MEA plate containing electrodes and then,
field potential can be measured. These field duration potentials ultimately equate and correlate
roughly to the QT interval in an in-vivo ECG and the action potential duration (APD) in-vitro
(Garg & Shrestha, 2018).
Fluorescence Imaging: Fluorescence microscopy methods can use Ca2+ or voltage-sensitive dyes
as a non-invasive method to measure intracellular ion fluctuations and voltage changes. A
difficulty that exists with this method is the potential binding of dyes to intracellular molecules
which can interfere with the normal functioning of the cell.
Impedance: Functional assays based on cellular impedance which is an indirect measure of
cardiac contractility, offers a noninvasive, label-free, and high throughput analysis method (MF,
SD, L, CW, & KL, 2015). Cells are seeded onto a multiwall cell culture plate that contains gold
film electrodes embedded onto the bottom of the wells. The mechanical displacement of the cells
during cardiomyocyte contraction is measured as variation in impedance otherwise measured as
a resistance in a current which also directly correlates with beating frequency.
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Figure 2. Platforms for functional analysis of human induced pluripotent stem cell-derived
cardiomyocytes (hiPSC-CMs). Graphical illustration summarizing different methods currently
used for hiPSC-CM functionality analyses. Patch clamp (A); multielectrode array (B; MEA);
fluorescence imaging (C); impedance (D). Representative MEA 78,79 and fluorescence imaging
80,81 traces (American Heart Association, 2015).
Without the presence of structural heart disease, this exploration aims to explore the life
threatening ventricular arrests that can lead to sudden cardiac death in LCHADD patients
especially in the younger adult population which can possibly arise as a result of concurrent
defects found in specialized membrane proteins called ion channels as suspected by some other
works of research (Garg, 2018). Changes in the function or expression of these channels in
cardiomyocytes could potentially disrupt the highly intricate and orchestrated electrical activity
of the heart which is why this study focuses on assessing the various functional platforms of
cardiomyocytes.

Results
A case series study was done to evaluate for cardiac risk factors by comparing LCHADD
patients who have experienced sudden cardiac arrest events (N=5) against those who have not
(denoted ‘controls,’ N=5). A plethora of hospitalization and general medical records were
reviewed including diagnostic testing, electrocardiograph (ECG) tests, heart rhythm strips,
18

plasma acylcarnitine levels, as well as the curation of a retrospective chart review of patient
medical records including metabolic panels, clinician notes, electrolytes, and specific symptoms
that were reported upon admission. The table below is followed by specific case details of each
of the young adult patients that experienced sudden cardiac death in the study.

Patients

Gender Cardiac Event Age at Event

Current
Age

Cardiac
Arrhythmias
VF, VT, long
QT, TdP

Significant
Admission Notes

4-5 days prior
nausea,
300,000 CK, acute
kidney injury,
seizure activity, was
VF, VT
in rhabdo upon
adm., 4-5 days prior
nausea
VF, VT, long Anxiety and panic
QT
attacks upon pres.
Found with seizure
VF, VT
activity

Course of
Pregnancy

Other Medical History

--

Blindness, neuropathy

--

300,000 CK, acute kidney
injury, seizure activity,
macular thinning

Case #1

M

YES

21

27

Case #2

M

YES

20

26

Case #3

M

YES

19

--

Case #4

M

YES

15

26

Case #5

F

YES

19

--

N/A

--

Coma @ 9mo

Rhabdomyolysis, periph.
retinopathy and neuropathy

Coma @ 10mo

Fatty liver,

ICU adm. @ 8mo
hypoglycemia
Pre-mature birth

Was found
ICU adm. @ 4
unconscious in
months, mother w/
basement and
HELLP
pronounced deceased

Control #1

F

NO

--

23

ST
abnormalities,
Diastolic
dysfunction

Control #2

M

NO

--

19

PVCs, SVT

Syncope, AVNRT,
respiratory illness, SICD

Control #3

M

NO

--

24

N/A

--

Control #4

F

NO

--

26

N/A

--

Control #5

F

NO

--

23

N/A

--

Retinitis, blindness,
anxiety, panic attacks
Retinopathy,
hydrocephalus
Retinopathy, increased
LFTs, rhabdomyolysis

ICU adm. @6mo
Rhabdomyolysis, myopathy
hypoglycemia
ICU adm. @ 4
Rhabdomyolysis,
months, mother w/
retinopathy, ear infections
HELLP
Premature 2mo,
Rhabdomyolysis
ICU adm.

Figure 3. A general overview of LCHADD patient data divided by individuals who experienced
sudden cardiac arrest and those who did not. Patients in red text indicate cases who experienced
SCD, and those in black are ‘controls’ who have not yet experienced a SCD event.

Case #1 was 21 years of age at their first cardiac event which included episodes of
ventricular fibrillations, sinus tachycardia, long-QT syndrome and potential suspicions of
torsades de pointes. Other medical histories regarding classic symptoms of LCHAD include
blindness, and neuropathy. This patient was diagnosed with LCHADD at 6 months of age
following initial presentation to the emergency room with jaundice, failure to thrive, and
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decreased activity. The diagnosis was confirmed by liver biopsy and subsequent fatty acid
oxidation flux studies in cultured hepatocytes with low LCHAD enzymatic activity. His
subsequent clinical history is remarkable for frequent recurrent rhabdomyolysis requiring
hospitalization multiple times per year throughout his lifetime. CKs range from 4000 to >40,000
during these episodes. Prior to their admission, the patient had increased levels of CK at around
2,700 U/L, and had been vomiting for approximately 7 hours prior to their hospitalization. Upon
admission, the patient was experiencing a significant decrease in cognition characterized by
decreased comprehension, and expression of language with delayed response and decreased
organization of language. The patient was found to be in torsade’s de pointes after one cardiac
event. An echocardiogram done on the patient showed ejection fraction down at 45-50%, with a
mildly enlarged right ventricle, and mildly reduced RV systolic function. Right ventricular
systolic pressure was noted to be calculated at 30.6 mmHg. Along with cardiac arrest-ventricular
fibrillation, acute respiratory failure was reported which required intubation and mechanical
ventilation. Additionally, the patient was found to be in sepsis secondary to aspiration
pneumonia. Case #1 was prescribed MCT oil and levocarnitine and is presumed to have been
compliant with this upon the time of admission.
Case #2 was 20 years of age at their first cardiac event which included ventricular
fibrillation bursts followed by a ventricular tachycardia arrest. In prior history, the patient was
known to have multiple hospital admissions for episodes of rhabdomyolysis. Before their event,
case #2 had been experiencing 4-5 days of nausea prior to their admission similar to case #1. Of
significant note was that case #2 was the only patient who was found to be in a severe case of
rhabdomyolysis upon admission with CK levels upwards of 300,000 U/L. Upon review of an
echocardiogram, the patient was noted to have systolic heart failure. The patient was also treated
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for anemia, pleural effusions, antibiotic associated diarrhea, and epistaxis. Their ejection fraction
demonstrated only mild decrease in systolic function and was suspected that some of their
cardiomyopathy is related to metabolic disturbances exacerbated by rhabdomyolysis however,
yet an unknown underlying result of LCHADD. The patient’s arrests had occurred in the setting
of acidosis and hyperkalemia related to rhabdomyolysis. Case #2 had been prescribed dietary
supplements including MCT oil, levocarnitine, DHA, vitamin D, and magnesium/calcium but,
was not compliant with these prescriptions at the time of the event.
Case #3 was 19 years of age at their first cardiac event. This patient had presented with
an ICU admission at 8 months of age to be treated for hypoglycemia and was also diagnosed
with LCHADD. In prior history, the patient has experienced retinopathy and blindness,
generalized anxiety, panic attacks, and admitted for various hospitalizations due to episodes of
rhabdomyolysis. The patient presented with an acute loss of consciousness and was found to be
in ventricular fibrillation upon arriving to the emergency department at their first cardiac event.
The patient was riding in a car as they complained of a headache, and then became unresponsive.
They were given 2 rounds of epinephrine as well as cardioversion and then transferred to another
medical center where the patient had several episodes of pulseless ventricular tachycardia which
resulted in the administration of amiodarone and subsequently resulted in seizure activity.
Following the seizures, the patient was administered fosphenytoin. An echocardiogram showed
normal left ventricular size with moderate to marked depression of systolic function as well as
normal right ventricular size with moderate depression of systolic function with no significant
valvular or pericardial issues. Following an evaluation by the hospital’s cardiology and
electrophysiology unit, an automatic implantable cardioverter defibrillator was placed one week
after their first admission. The patient had a past medical history of premature retinopathy and a
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hydrocephalus which required a VP shunt. The patient was not on any home medications prior to
hospitalization including any dietary supplements.
Case #4 was 15 years of age at their first cardiac event which presented with ventricular
fibrillation and tachycardia arrest, and prolonged QTc interval. The patient had a pre-mature
birth at approximately 10 months with a prior history of retinopathy and hydrocephalus. Upon
admission, case #4 experienced an acute deterioration of EF from 50% to 20% over the course of
1 week during the admission which had ultimately led to cardiac arrest, 30 minutes of CPR,
intubation for 11 days and ECMO therapy. They were hemodynamically stable since their
extubation however the patient now has hoarseness and dysphagia to thin liquids. Upon
hospitalization, the patient was noted to have a short run of VT (6 beats), and an evaluation of an
ECHO that showed poor function. The patient had numerous hospitalization due to recurring
cases of rhabdomyolysis. Their sudden cardiac arrest event was in the presence of an episode of
rhabdomyolysis. The patient had also been experiencing retinitis, joint pain, blindness, and
abnormality of gait. Of significant note is the patients recurring anxiety/diaphoresis/weakness
and recent physical deterioration and decreased mobility. Case #4 was prescribed levocarnitine,
MCT oil, and vitamin D and E tablets however it is unclear whether the patient was compliant
with the medications upon hospitalization for their cardiac death event.
Case #5 was 19 years of age when they were unexpectedly found dead in the basement of
their house. An autopsy report determined that the specific cause was unclear although due to an
unknown, underlying condition of LCHADD. The patient had a classical presentation during
early infancy with an ICU admission at four months of age with retinopathy and frequent
episodes of rhabdomyolysis. The patient’s mother had also died from increased LFTs due to
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HELLP syndrome, Case #5 was prescribed MCT oil, carnitine, cod liver oil, and vitamin A,
however, was not compliant with these in recent history.
Results for each of the sudden cardiac arrest events were compared against five ‘controls’
who were also young adult patients with LCHADD but, had not yet experienced any sudden
cardiac arrest events besides control #3 who had experienced some premature ventricular
contractions but no, complete cardiac death as experienced by all 5 cases in the study. All of the
controls are of similar age to the cases who experienced sudden cardiac arrest however, there
does not appear to be any significant differences in the course of the disease between the two
populations. Both populations were prescribed and ordered to follow a strict diet and upon
retrospective case review, 3/5 those who experienced sudden cardiac reported failure to keep up
with their medications upon the time of admission for their cardiac events. Figure 4 illustrates the
supplements that were prescribed to the two populations and their compliance. Both groups were
prescribed similar dietary supplements and this does not appear to be influencing the nature of
cardiac arrythmias in patients. To supplement this data, elevated carnitine levels can be seen in
cases as indicated by the increased carnitine ratios in figure 4 that depict cases to have ratios >1
and controls with ratios <1. These results are limited in their ability to deduce sound conclusions
of why cases are more likely than controls to experience sudden cardiac arrest due to the time
upon when certain medical records were measured in patients; not all data points were retrieved
upon initial hospital admissions and, some data points relied on prior test results which could
have been extremely different to levels upon presentation of a cardiac arrest event.
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Figure 4. A list of the prescribed supplements to be taken by the LCHADD patients included in
the study.

Figure 5. Various measures of carnitine levels in LCHADD patients (μMol/L). Patients in red are
patients who are cases and those in blue are ‘control’ patients who have not yet experienced
sudden cardiac death.

Anticipated Effects on Mitochondrial Function in iPSC-CMs &
Discussion
Due to the impacts of COVID-19, further generation of cardiomyocytes was halted in the
prior months prohibiting the advancement of this data acquisition. However, anticipated impacts,
results and the rationale behind the exploration of various mitochondrial functions in LCHAD
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deficient cardiomyocytes is described below. These various parameters and measurements are
compared between LCHAD deficient cardiomyocytes and normal cardiomyocytes derived from
wild type (WT) cells that are healthy.
For the exploration of bioenergetic impacts. we anticipate that LCHADD cardiomyocytes
will have similar oxygen consumption and ATP production as WT cells under high glucose
conditions. However, we hypothesize the LCHADD cardiomyocytes will have lower O2
consumption and ATP production compared to WT cells under conditions of low glucose/fatty
acid supplemented media.
Following the completion of various functional assessment platforms, we anticipate that
LCHADD cardiomyocytes will have similar functional parameters during patch clamp, MEA,
fluorescent imaging and impedance as WT cells under high glucose conditions. However, we
hypothesize the LCHADD cardiomyocytes will have altered functional analysis with lower
contractile force compared to WT cells under conditions of low glucose/fatty acid supplemented
media.
As described, some areas of research suggest that toxic byproducts can accumulate as a
result of FAODs. With this consideration, we anticipate LCHADD cardiomyocytes will have
elevated long-chain, 3-OH acylcarnitines in all conditions but that these metabolites will increase
dramatically during low glucose/fatty acid supplemented media conditions. Elevated partially
oxidized metabolites will be associated with increased ROS, acidosis, and increased lactate.
It is possible other mechanisms in addition to energetic deficiencies could contribute to
the pathophysiology of the severe cardiac manifestations reported here in young adult LCHADD
patients. Mitochondrial stress and accumulation of toxic metabolites such as long-chain hydroxy
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FAs or carnitine due to inborn errors of metabolism that could potentially lead to severe cardiac
death in LCHADD patients (Spiekerkoetter & Wood, 2010). Wajner summarized the potential
mechanisms that affect energy homeostasis and suggests a potential explanation of the
pathophysiology of the disease. Mechanisms included altered redox reactions, fatty acid
accumulation, acidity, calcium and potassium homeostasis, as well as derangements in
bioenergetics. Understanding the role of accumulated fatty acids metabolites as a crucial player
in altered bioenergetics of the cells as well as its role in inducing mitochondrial dysfunction are
crucial in understanding why LCHAD deficient patients may develop these dysregulations. In
the study by Wajner, alterations were seen in biochemical processes in mice liver, muscle, and
heart tissues. If cardiomyocytes with a mature phenotype were successfully developed, some
anticipated results of the assessment of cardiomyocytes could include a decrease in force of
contraction, decreased calcium retention capacities, erratic beating patterns, and severe
mitochondrial defects.
Typically, upon diagnosis and treatment in the pre- and post-natal stages of LCHADD,
cardiomyopathy is typically resolved and patients go on to report normal cardiac function in
childhood. This exploration of sudden ventricular tachycardia in this young adult population with
LCHADD ranging in ages between 16 and 23 years is one that is unique and not currently
described in the literature. Following the retrospective case study review, we report minor
differences in supplements and carnitine levels between cases and controls as well as minor
electrolyte derangements that were seen. However, we hypothesize that unidentified underlying
cardiac risk factors that increase the risk for sudden cardiac death continue to exist. It is
important to consider that this study exemplifies that sudden cardiac arrest can occur in any
setting and is not exacerbated through other severe symptoms often accompanied with LCHADD
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patients including episodes of rhabdomyolysis or varied adherence to supplements and diets
prescribed. Applications and exploration of this topic using stem cell technology to generate
beating cardiomyocytes provides a promising model to investigate this severe cardiac
manifestation and its potential molecular mechanisms. Future directions of this study will pick
up where we left off before the spread of COVID-19 to produce phenotypically mature
cardiomyocytes as well as to obtain thorough and complete data for this critically vulnerable
population. Future anticipated clinical trials that have been approved by the IRB will include
data from cardiac magnetic resonance imaging of the heart, results of ECG bicycle exercise
stress tests, measures of acylcarnitine levels before and after these tests, and blood draws to
perform thorough laboratory studies and measurement of patients’ electrolytes, glucose, insulin,
creatine kinase, free fatty acids, lactate, pyruvate, ketones and plasma/serum acylcarnitine levels.
Following the acquisition of sound patient data through clinical trials along with the
establishment of a mature cardiomyocyte model to explore potential mechanisms, our research
group will further contribute to the limited understanding of this very severe cardiac
manifestation exhibited in patients with FAODs like LCHADD.
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